The CAS SciFinder Discovery Platform expansion unlocks human-indexed insights from journals and patents in over 50 languages dating back to 1957 and 70 million biosequences curated by CAS scientists
It would be the first protein-based alternative available in Israel
The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
